Acella Issues Voluntary Nationwide Recall of Certain Lots of Thyroid Tablets Due to Sub Potency
May 4, 2021
Acella Pharmaceuticals is voluntarily recalling certain lots of its thyroid tablets to treat hypothyroidism after routine testing found these lots had lower than expected potency.
The product contains less than 90 percent of the labeled amount of liothyronine (T3) and/or levothyroxine (T4).
Patients being treated for hypothyroidism (underactive thyroid), who receive sub potent NP Thyroid, may experience signs and symptoms of hypothyroidism, which may include, fatigue, increased sensitivity to cold, constipation, dry skin, puffy face, hair loss, slow heart rate, depression, swelling of the thyroid gland and/or unexplained weight gain or difficulty losing weight.
To date, Acella has received 43 reports of serious adverse events that could possibly be related to this recall.
NP Thyroid, Thyroid Tablets, USP is composed of levothyroxine and liothyronine, and used to treat hypothyroidism (underactive thyroid). The products subject to recall are packed in 100-count and 7-count bottles.
A full list of the lot numbers and packaging photos can be found on the U.S. Food and Drug Administration website.
Patients who are currently taking NP Thyroid from the lots being recalled should not discontinue use without contacting their healthcare provider for further guidance and/or a replacement prescription.
Further information can be found by contacting Acella Pharmaceuticals via email at [email protected] or by calling 1-888-424-4341.
Author: Rare Daily Staff
Sign up for updates straight to your inbox.